| Combination of | |
|---|---|
| Artesunate | Antimalarial |
| Pyronaridine | Antimalarial |
| Clinical data | |
| Trade names | Pyramax [1] |
| Other names | Artesunate/pyronaridine tetraphosphate [1] |
|
Routes of administration | By mouth [2] |
| ATC code | |
| Identifiers | |
| CAS Number | |
Artesunate/pyronaridine, sold under the brand name Pyramax, is a fixed-dose combination medication for the treatment of malaria. [3] [1] It can be used for malaria of both the P. falciparum and P. vivax types. [1] It combines artesunate and pyronaridine. [3] It is taken by mouth. [2]
The combination is generally well tolerated. [1] Side effects may include headache, vomiting, or cough. [1] Use in those with severe liver disease or kidney disease is not recommended. [2] Use is not generally recommended in early pregnancy. [2] However, there are no other options and if treatment may save the mother's life it may be used. [2] The two components work by different mechanisms. [2]
It is on the World Health Organization's List of Essential Medicines. [3]
Medical uses
Artesunate/pyronaridine is used for malaria of both the P. falciparum and P. vivax types. [1] It is not recommended for severe disease. [2]
A 2019 review (updated in 2021) found that the combination compared well to artemether/lumefantrine. [4] Benefits also appear similar to mefloquine together with artesunate. [4] It is not recommended for the prevention of malaria. [2]
Research for drug repurposing
There is some in vitro evidence that suggests artesunate/pyronaridine may be worthy of clinical trial study to determine whether it might have a role as a drug for COVID-19 treatment. [5]
References
- ^ a b c d e f g "Application for inclusion in the WHO Model List of essential medicines" (PDF). WHO. Nov 2010. Retrieved 29 June 2017.
- ^ a b c d e f g h "Pyramax 180 mg/60 mg Film-coated tablet" (PDF). EMA. Archived from the original (PDF) on 14 December 2017. Retrieved 13 December 2017.
- ^ a b c World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ^ a b Pryce J, Taylor M, Fox T, Hine P (June 2022). "Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria". The Cochrane Database of Systematic Reviews. 2022 (6): CD006404. doi: 10.1002/14651858.CD006404.pub4. PMC 9209011. PMID 35726133.
- ^ Krishna S, Augustin Y, Wang J, Xu C, Staines HM, Platteeuw H, et al. (January 2021). "Repurposing Antimalarials to Tackle the COVID-19 Pandemic". Trends in Parasitology. 37 (1): 8–11. doi: 10.1016/j.pt.2020.10.003. PMC 7572038. PMID 33153922.
